Saphris regulatory update

The Scottish Medicines Consortium recommended against the use of Sycrest asenapine from marketing partner H. Lundbeck A/S (CSE:LUN, Copenhagen, Denmark) on the National Health Service (NHS) in Scotland to treat moderate to severe manic episodes associated with bipolar I disorder. The agency said that Lundbeck did not present a sufficiently robust economic analysis. ...